FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W428857> ?p ?o ?g. }

• W428857 endingPage "6" @default.
• W428857 startingPage "311" @default.
• W428857 abstract "Chronic systemic inflammation plays a pivotal role in the development of atherosclerosis in rheumatoid arthritis (RA). In the present study, we investigated whether anti-TNF-alpha antagonist-monoclonal antibody-infliximab administration alters circulating levels of resistin, a proinflammatory adipokine. We further assessed associations of circulating resistin concentrations with CRP and ESR levels, platelet counts and metabolic syndrome and demographic characteristics in RA patients on periodical treatment with infliximab.We investigated 33 patients with RA on periodical treatment with infliximab. Serum resistin levels were determined immediately prior to and after infliximab infusion.Upon infliximab administration, mean (SD) serum resistin concentrations (ng/ml) decreased from 21.9 (9.9) to 17.4 (8.9) (p=0.005). Also, a significant association between the mean ESR (r=0.405; p=0.03) and CRP (r=0.571; p=0.0005) from disease diagnosis and ESR (r=0.486; p=0.004), CRP (r=0.599; p=0.0005) and platelet count (r=0.559; p=0.0007) at the time of the study and baseline resistin levels was found.The present study shows that anti-TNF-alpha therapy results in a rapid reduction of serum resistin levels in patients with RA. It also confirms a close association between laboratory markers of inflammation, particularly CRP and resistin levels. These observations support a potential role of resistin in the inflammatory cascade in RA." @default.
• W428857 created "2016-06-24" @default.
• W428857 creator A5015159950 @default.
• W428857 creator A5016922988 @default.
• W428857 creator A5025333421 @default.
• W428857 creator A5038298926 @default.
• W428857 creator A5045602014 @default.
• W428857 creator A5051418515 @default.
• W428857 creator A5055239092 @default.
• W428857 creator A5058491323 @default.
• W428857 creator A5076108618 @default.
• W428857 date "2008-06-21" @default.
• W428857 modified "2023-10-18" @default.
• W428857 title "Anti-TNF-alpha therapy modulates resistin in patients with rheumatoid arthritis." @default.
• W428857 cites W1515255326 @default.
• W428857 cites W1675830194 @default.
• W428857 cites W1708748675 @default.
• W428857 cites W1750895917 @default.
• W428857 cites W1785226454 @default.
• W428857 cites W1964044812 @default.
• W428857 cites W1996472975 @default.
• W428857 cites W2004997688 @default.
• W428857 cites W2014266615 @default.
• W428857 cites W2015025775 @default.
• W428857 cites W2026730648 @default.
• W428857 cites W2032257407 @default.
• W428857 cites W2072117604 @default.
• W428857 cites W2097796010 @default.
• W428857 cites W2099559598 @default.
• W428857 cites W2102935782 @default.
• W428857 cites W2110678596 @default.
• W428857 cites W2118336146 @default.
• W428857 cites W2137499656 @default.
• W428857 cites W2139889887 @default.
• W428857 cites W2149849190 @default.
• W428857 cites W2152348310 @default.
• W428857 cites W2152746369 @default.
• W428857 cites W2160427887 @default.
• W428857 cites W2166376415 @default.
• W428857 cites W2170874916 @default.
• W428857 cites W2292025369 @default.
• W428857 cites W54474866 @default.
• W428857 cites W65358577 @default.
• W428857 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18565254" @default.
• W428857 hasPublicationYear "2008" @default.
• W428857 type Work @default.
• W428857 sameAs 428857 @default.
• W428857 citedByCount "31" @default.
• W428857 countsByYear W4288572012 @default.
• W428857 countsByYear W4288572013 @default.
• W428857 countsByYear W4288572014 @default.
• W428857 countsByYear W4288572015 @default.
• W428857 countsByYear W4288572016 @default.
• W428857 countsByYear W4288572017 @default.
• W428857 countsByYear W4288572018 @default.
• W428857 countsByYear W4288572019 @default.
• W428857 countsByYear W4288572022 @default.
• W428857 crossrefType "journal-article" @default.
• W428857 hasAuthorship W428857A5015159950 @default.
• W428857 hasAuthorship W428857A5016922988 @default.
• W428857 hasAuthorship W428857A5025333421 @default.
• W428857 hasAuthorship W428857A5038298926 @default.
• W428857 hasAuthorship W428857A5045602014 @default.
• W428857 hasAuthorship W428857A5051418515 @default.
• W428857 hasAuthorship W428857A5055239092 @default.
• W428857 hasAuthorship W428857A5058491323 @default.
• W428857 hasAuthorship W428857A5076108618 @default.
• W428857 hasConcept C126322002 @default.
• W428857 hasConcept C134018914 @default.
• W428857 hasConcept C170493617 @default.
• W428857 hasConcept C17991360 @default.
• W428857 hasConcept C194832188 @default.
• W428857 hasConcept C203014093 @default.
• W428857 hasConcept C2776885963 @default.
• W428857 hasConcept C2777077863 @default.
• W428857 hasConcept C2777575956 @default.
• W428857 hasConcept C2779760629 @default.
• W428857 hasConcept C2780613262 @default.
• W428857 hasConcept C511355011 @default.
• W428857 hasConcept C71924100 @default.
• W428857 hasConcept C90924648 @default.
• W428857 hasConceptScore W428857C126322002 @default.
• W428857 hasConceptScore W428857C134018914 @default.
• W428857 hasConceptScore W428857C170493617 @default.
• W428857 hasConceptScore W428857C17991360 @default.
• W428857 hasConceptScore W428857C194832188 @default.
• W428857 hasConceptScore W428857C203014093 @default.
• W428857 hasConceptScore W428857C2776885963 @default.
• W428857 hasConceptScore W428857C2777077863 @default.
• W428857 hasConceptScore W428857C2777575956 @default.
• W428857 hasConceptScore W428857C2779760629 @default.
• W428857 hasConceptScore W428857C2780613262 @default.
• W428857 hasConceptScore W428857C511355011 @default.
• W428857 hasConceptScore W428857C71924100 @default.
• W428857 hasConceptScore W428857C90924648 @default.
• W428857 hasIssue "2" @default.
• W428857 hasLocation W4288571 @default.
• W428857 hasOpenAccess W428857 @default.

• next